Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands

Vaccine

Volumn 30, Issue 31, 2012, Pages 4691-4700

  Meijboom, M J ^a,b   Rozenbaum, M H ^a   Benedictus, A ^b   Luytjes, W ^c   Kneyber, M C J ^d,e   Wilschut, J C ^b   Hak, E ^a,b   Postma, M J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e Groningen Research Institute for Asthma and COPD   (Netherlands)

Author keywords

Cost effectiveness analyses; Cost utility analyses; Modeling policy making Netherlands infants; RSV

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SENSITIVITY ANALYSIS; VACCINATION;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; INFANT; MODELS, ECONOMIC; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; VACCINATION;

EID: 84861986082     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.072     Document Type: Article

References (48)

1. Kimpen J.L. Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing. Respiratory Research 2002, 3(Suppl 1). p.S40-5.
2. Simoes E.A. Respiratory syncytial virus infection. Lancet 1999, 354(9181):847-852.
3. Jansen A.G., et al. Rate-difference method proved satisfactory in estimating the influenza burden in primary care visits. Journal of Clinical Epidemiology 2008, 61(8):803-812.
4. Jansen A.G., et al. Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. European Respiratory Journal 2007, 30(6):1158-1166.
5. Rietveld E., et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatric Infectious Disease Journal 2004, 23(6):523-529.
6. Rietveld E., et al. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatric Infectious Disease Journal 2006, 25(3):201-207.
7. Assink M.D., et al. Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination. Vaccine 2009, 27(7):1119-1126.
8. Hall C.B., et al. Immunity to and frequency of reinfection with respiratory syncytial virus. Journal of Infectious Diseases 1991, 163(4):693-698.
9. Weber A., Weber M., Milligan P. Modeling epidemics caused by respiratory syncytial virus (RSV). Mathematical Biosciences 2001, 172(2):95-113.
10. Fleming D.M., Elliot A.J., Cross K.W. Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods. Epidemiology and Infection 2007, 135(7):1099-1108.
11. Kneyber M.C.J., et al. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatrica 2000, 89(6):654-660.
12. Bont L., Aalderen W.M., Kimpen J.L. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatric Respiratory Reviews 2000, 1(3):221-227.
13. Bloemers B.L., et al. High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection. Pediatric Infectious Disease Journal 2010, 29(1):39-42.
14. Fleming D.M., Pannell R.S., Cross K.W. Mortality in children from influenza and respiratory syncytial virus. Journal of Epidemiology and Community Health 2005, 59(7):586-590.
15. RIVM. RSV-infectie (respiratoir syncytiaal virus). 2009, [Accessed on: 29-6-2009]; Available from: . http://www.rivm.nl/cib/infectieziekten-A-Z/infectieziekten/RSV_infectie@28respiratoir-syncytiaalvirus@29/index.jsp.
16. Committee for Pharmaceutical Help, CVZ. Pharmaco economic evaluation of palivizumab. [Accessed on: 28-9-2009]; Available from: . http://www.cvz.nl/binaries/live/CVZ_Internet/hst_content/nl/documenten/cfh-rapporten/2006/rpt0609+palivizumab-Synagis.pdf.
17. Kim H.W., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. American Journal of Epidemiology 1969, 89(4):422-434.
18. Delgado M.F., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Medicine 2009, 15(1):34-41.
19. Waris M.E., et al. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. Journal of Virology 1996, 70(5):2852-2860.
20. Acedo L., et al. Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications. Epidemiology and Infection 2010, 138(6):853-860.
21. Bos J.M., et al. The use of health economics to guide drug development decisions: determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach. Vaccine 2007, 25(39-40):6922-6929.
22. Bont L., et al. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatric Infectious Disease Journal 2004, 23(5):414-417.
23. Sigurs N., et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. American Journal of Respiratory and Critical Care Medicine 2005, 171(2):137-141.
24. Tarride J.E., et al. A review of health utilities across conditions common in paediatric and adult populations. Health Qual Life Outcomes 2010, 8:12.
25. RIVM. Sterfte, ziekte en ziektelast voor 56 geselecteerde aandoeningen. Nationaal Kompas Volksgezondheid. 2003, [Accessed on: 2009]; Available from: . http://www.rivm.nl/vtv/object_document/o4237n16906.html.
26. Greenough A., et al. Health care utilisation of prematurely born: preschool children related to hospitalisation for RSV infection. Archives of Disease in Childhood 2004, 89(7):673-678.
27. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FHH. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg [Guidelines for costing research, methods and standardized prices for economic evaluations in health care], ed. C.v.Z.H.I. Board. 2004: CVZ, Diemen, the Netherlands.
28. Koopmanschap M.A., et al. The friction cost method for measuring indirect costs of disease. Journal of Health Economics 1995, 14(2):171-189.
29. Miedema C.J., et al. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatric Infectious Disease Journal 2001, 20(2):160-163.
30. Briggs A., Claxton K., Sculpher M. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
31. Jit M., Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011, 29(5):371-386.
32. Rozenbaum M.H., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:c2509.
33. Greenough A., et al. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants. Thorax 2009, 64(6):490-495.
34. van der Zalm M.M., et al. Respiratory pathogens in respiratory tract illnesses during the first year of life: a birth cohort study. Pediatric Infectious Disease Journal 2009, 28(6):472-476.
35. Bourgeois F.T., et al. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics 2009, 124(6):e1072-e1080.
36. Nicholson K.G., et al. Rates of hospitalisation for influenza: respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006, 24(1):102-108.
37. Deshpande S.A., Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Archives of Disease in Childhood 2003, 88(12):1065-1069.
38. Hall C.B., et al. The burden of respiratory syncytial virus infection in young children. New England Journal of Medicine 2009, 360(6):588-598.
39. Boyce T.G., et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. Journal of Pediatrics 2000, 137(6):865-870.
40. Lee M.S., Walker R.E., Mendelman P.M. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children, implications for design of vaccine trials. Human Vaccines 2005, 1(1):6-11.
41. Iwane M.K., et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus: influenza virus, and parainfluenza viruses among young children. Pediatrics 2004, 113(6):1758-1764.
42. Leader S., Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations: 1997 to 1999. Pediatric Infectious Disease Journal 2002, 21(7):629-632.
43. Kristensen K., et al. Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. Pediatric Infectious Disease Journal 1998, 17(11):996-1000.
44. Weigl J.A., Puppe W., Schmitt H.J. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. European Journal of Clinical Microbiology and Infectious Diseases 2001, 20(7):452-459.
45. Thompson W.W., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003, 289(2):179-186.
46. Howard T.S., et al. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. Journal of Pediatrics 2000, 137(2):227-232.
47. Verboon-Maciolek M.A., et al. Clinical and epidemiologic characteristics of viral infections in a neonatal intensive care unit during a 12-year period. Pediatric Infectious Disease Journal 2005, 24(10):901-904.
48. Stein R.T., et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354(9178):541-545.